Top 5, as of May 26:
- China’s CanSino adenovirus vaccine currently leads the pack — although there was a notable stumbling block in its May 22 results
- Oxford University’s adenovirus vaccine candidate has slipped into second place — but Oxford just attracted a $1 billion bet from BARDA
- Moderna’s much-vaunted mRNA platform reported some early results on May 18 — but can future results live up to the hype for what is an entirely new vaccine technology?
- Maybe the safest bet is to use the long-proven route of an inactivated virus vaccine — if so, the Chinese company Sinovac is the one to watch
- Inovio’s May 20 DNA vaccine candidate results looked highly promising: some have said this is a ‘moon shot’ but that has worked before…
No comments:
Post a Comment